13F Holdings
中文EN

PCRX Pacira BioSciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1396814 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY3.7%
TTM net income YoY76.0%
TTM EPS YoY97.9%
Revenue 3-yr CAGR3.7%
Net income 3-yr CAGR75.5%

Margins

Gross margin78.7%
Operating margin4.8%
Net margin5.1%
FCF margin22.7%
EBITDA margin12.4%

Returns

ROE5.2%
ROA3.0%
ROIC (approx.)4.2%
Asset turnover0.59x

Leverage & solvency

Liabilities / assets40.8%
Debt / equity0.41x
Current ratio4.68x
Interest coverage2.54x

Cash quality & payout

Operating cash flow / net income4.69x
Accruals ratio-11.1%
Payout ratio—
Capex / revenue1.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$726.41M$700.97M$674.98M$666.82M$541.53M
Cost of revenue$149.75M$170.43M$184.67M$199.29M$140.25M
Gross profit$576.66M$530.54M$490.31M$467.53M$401.28M
R&D expense$117.31M$81.58M$76.26M$84.80M$55.55M
SG&A expense$368.76M$294.10M$269.44M$254.52M$199.34M
Operating income$19.19M-$73.37M$87.67M$60.02M$89.92M
Interest expense$17.45M$16.57M$20.31M$39.98M$31.75M
Pretax income$16.87M-$63.11M$61.70M$13.30M$56.40M
Income tax$9.84M$36.45M$19.75M-$2.61M$14.42M
Net income$7.03M-$99.56M$41.95M$15.91M$41.98M
EBITDA$110.21M$5.41M$163.25M$151.53M$118.47M
EPS (basic)0.16-2.150.910.350.95
EPS (diluted)0.16-2.150.890.340.92
Weighted avg. shares (diluted)45.04M46.24M51.98M46.54M45.63M
Balance sheet
Cash & equivalents$158.54M$276.77M$153.30M$104.14M$585.58M
Short-term investments$79.88M$207.84M$125.28M$184.51M$70.83M
Receivables$124.07M$113.30M$105.56M$98.40M$96.32M
Inventory$152.86M$125.28M$104.35M$96.06M$98.55M
Current assets$547.97M$745.13M$509.99M$498.33M$866.05M
PP&E, net$140.69M$167.17M$173.93M$183.51M$188.40M
Goodwill$20.21M$0$163.24M$163.24M$145.20M
Intangibles$368.10M$425.97M$483.26M$540.55M$623.97M
Total assets$1.26B$1.55B$1.57B$1.68B$2.08B
Current liabilities$120.59M$309.92M$97.38M$147.77M$521.12M
Short-term debt$0$201.78M———
Long-term debt$372.19M$383.55M$522.44M$689.47M—
Total debt$372.19M$585.32M$522.44M$689.47M—
Total liabilities$571.81M$775.17M$704.26M$906.19M$1.34B
Shareholders' equity$693.11M$778.35M$870.13M$775.01M$730.41M
Net debt$213.64M$308.55M$369.14M$585.33M—
Shares outstanding41.12M46.24M46.48M45.93M44.73M
Cash flow statement
Operating cash flow$151.99M$189.39M$154.65M$145.27M$125.72M
Capital expenditure$15.33M$10.64M$15.16M$30.08M$45.87M
Free cash flow$136.66M$178.75M$139.49M$115.20M$79.85M
Investing cash flow$99.48M-$83.28M$77.54M-$225.19M-$20.79M
Financing cash flow-$369.63M$17.36M-$183.03M-$401.53M$380.69M
Depreciation & amortization$91.02M$78.78M$75.57M$91.50M$28.55M
Stock-based compensation$57.50M$51.17M$47.90M$48.09M$42.25M
Share buybacks$148.33M$25.00M$0$0—

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.